A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

404

Participants

Timeline

Start Date

January 27, 2015

Primary Completion Date

September 17, 2016

Study Completion Date

September 17, 2016

Conditions
Parkinson's Disease
Interventions
DRUG

TVP-1012 1mg

TVP-1012 1mg Tablets

DRUG

TVP-1012 0.5mg

TVP-1012 0.5mg Tablets

DRUG

Placebo

Placebo Tablets

Trial Locations (57)

Unknown

Nagoya

Matsuyama

Touon

Kitakyushu

Onoshiro

Aizu-Wakamatsu

Fujioka

Asahikawa

Iwamizawa

Sapporo

Akashi

Kobe

Tsukuba

Morioka

Takamatsu

Fujisawa

Kawasaki

Sagamihara

Nankoku

Gōshi

Sendai

Matsumoto

Higashisonogi-gun

Jōetsu

Yufu

Higashiosaka

Hirakata

Suita

Takatsuki

Toyonaka

Irima-gun

Fuji

Hamamatsu

Izunokuni

Shimono

Yoshinogawa

Bunkyo-ku

Fuchū

Kodaira

Nerima-ku

Ōta-ku

Setagaya-ku

Shibuya-ku

Akita

Aomori

Chiba

Fukuoka

Fukushima

Hiroshima

Kyoto

Miyazaki

Niigata

Okayama

Osaka

Tokushima

Toyama

Wakayama

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY